Rapid tests supply our frontline caregivers a needed tool in fighting the coronavirus outbreak. Simple tests taking less than 15 minutes, performed at the patient's bedside, confirming if a patient has COVID-19 allows doctors to make informed care decisions. Some of these test formats are immunochromatographic assays more commonly known as lateral flow tests. Only a couple of these tests have been approved for use by the CDC but many more are being reviewed. Demand for SARS-CoV-2 lateral flow tests is high and expected to increase throughout the coming months.
BioDot has been able to respond to the growing rapid test demand with products for high volume lateral flow test manufacturing equipment.
“We are very proud of the contribution that our products are making in this global healthcare fight. We have been working closely with test developers to quickly bring on increased manufacturing capabilities,” comments Kelly Tisone, VP Marketing.
BioDot manufactures equipment used in the production of rapid tests in Irvine, California, USA.
During this critical period BioDot has been able to continue operations and is dedicated to meeting the growing demand.